bluebird bio (NASDAQ:BLUE) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
bluebird bio Earnings Cheat Sheet
Revenue: Rose 77.46% to $6.3 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: bluebird bio reported adjusted EPS income of $2.13 per share. By that measure, the company beat the mean analyst estimate of $-0.35. It beat the average revenue estimate of $4.48 million.
Quoting Management: “bluebird has made substantial progress during the first half of 2013 both operationally and in the clinic,” stated Nick Leschly, Chief bluebird. “In June, we completed our initial public offering, strengthening our balance sheet and attracting a number of new shareholders. We are now focused on initiating two additional clinical trials in the second half of 2013, including our phase 2/3 CCALD study with Lenti-D.”
Key Stats (on next page)…